FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Horizon Technology Finance Provides $15MM Venture Loan to Tallac Therapeutics

August 07, 2023, 05:00 AM
Filed Under: Biotechnology

Horizon Technology Finance provided a $15 million venture loan facility to Tallac Therapeutics, Inc., of which $5 million has been initially funded.

Tallac is developing multiple novel immunotherapies to fight cancer. Tallac's innovative Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform enables systemic delivery of differentiated TLR9 agonists to activate a specific anti-cancer immune response for various solid tumor malignancies. Tallac is backed by premier investors including venBio, Lightstone Ventures, Morningside and MRL Ventures Fund. The company will use the loan proceeds for general growth and working capital purposes.

"Tallac is advancing new immunotherapies that may make a tremendous difference in the ongoing fight against cancer," said Gerald A. Michaud, President of Horizon. "Through the development of antibody conjugate-based therapeutics, Tallac's best-in-class therapies attempt to trigger innate and adaptive immune responses to best address the needs of patients. We are pleased to support Tallac's continued work and its vital mission."

"We are pleased to have Horizon's support as we continue to make excellent progress in our TRAAC platform and programs," said Hong I. Wan, Ph.D., president, CEO and co-founder of Tallac Therapeutics. "We are excited to further progress our lead program, TAC-001, in the clinic and to advance additional agents to find difficult-to-treat cancers."

Week's News

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.